Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24
Key facts
- Who runs it
- Sanofi
- Where
- Finland and Germany11 sites in 2 countriesChoose a country to see its sites
- Trial code
- NCT06059456
- U1111-1280-6036
- Status
- Completed
- People taking part
- 2,078 people enrolled
- Started
- 2 Oct 2023
- Ended
- 15 Dec 2023
- Type of study
- Observational, 2 groups
- Treatments tested
- Quadrivalent Influenza Vaccine
- High-Dose Quadrivalent Influenza Vaccine
- Record updated
- 24 March 2025
Who can take part
- Age
- 6 months and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- There are no formal inclusion criteria. Individuals who approach the site for vaccination and agree to receive a vaccination card will be included and vaccinated with the respective vaccine brand according to the country of their location, recommendations for the individual vaccines as well as national recommendations
Who cannot take part
- -
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This EPSS will determine the vaccinee reporting rates (RRs) of suspected ADRs following routine vaccination with VaxigripTetra® and Efluelda® respectively, during the NH influenza season 2023/24. The primary objective of this surveillance is to estimate the vaccinee reporting rate (RR) of suspected adverse drug reactions (ADRs) occurring within 7 days following routine vaccination with VaxigripTetra® and Efluelda® respectively, during the Northern Hemisphere (NH) influenza season 2023/24. Study duration per participant 2 months (including 6 weeks for VC distribution 2 weeks for vaccinee reporting) following the first vaccination
The 2 groups in the trial
- VaxigripTetra®
Participant vaccinated with VaxigripTetra® as per routine clinical practice
Treatment: Quadrivalent Influenza Vaccine
- Efluelda®
Participant vaccinated with Efluelda® as per routine clinical practice
Treatment: High-Dose Quadrivalent Influenza Vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (High Dose Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2023/24
- Record updated
- 24 March 2025